Several new variants of SARS-CoV-2 virus have emerged in recent months. The Alpha, Gamma, Beta, Delta, and the most recent Omicron are particular concerning because of their high prevalence.

A subset of the mutations identified in the RBD domain of the spike protein occurs in more than one strain, These convergent mutations are of high interest because they may be the cause of the increased transmissibility. Sino Biological has launched RBD and Spike proteins of these variants.

The mutations in these strains also occur in the nucleocapsid protein, which is commonly used as the biomarker in rapid antigen tests. It’s critical to assess whether the current commercial antigen tests can detect the mutated N proteins with the same sensitivity and specificity as their WT counterpart.

Sino Biological has developed recombinant Omicron Spike RBD Protein and Antibody reacting with Omicron to support the study of Omicron variant.